About the Company
We do not have any company description for Design Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DSGN News
Q4 2023 Design Therapeutics Inc Earnings Call
Sean Jeffries; COO; Design Therapeutics, Inc. Pratik Shah; Co-Founder, President, and Chairperson; Design Therapeutics, Inc. Operator And welcome to design's conference call at this time.
DSGN Design Therapeutics, Inc.
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today provided an update on ...
Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress
Warning! GuruFocus has detected 2 Warning Signs with DSGN. On March 19, 2024, Design Therapeutics Inc (NASDAQ:DSGN) released its 8-K filing, outlining significant progress across its GeneTAC ...
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development -HUNTSVILLE, AL, April 17, 2024 ...
Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript
Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript March 19, 2024 Design Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.32.
Design Therapeutics Inc DSGN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript
Design Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.32. DSGN isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript
I would now like to turn the call over to Dr. Sean Jeffries, Chief Operating Officer of Design Therapeutics. You may begin. Welcome and thank you for joining us today. Earlier, we issued a press ...
Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript
And that’s what’s so exciting about Design, is we have an opportunity to provide a restorative therapy of natural frataxin from the patient’s own genes and to do it with a small molecule.
Q4 2023 Design Therapeutics Inc Earnings Call
Sean Jeffries; COO; Design Therapeutics, Inc. Pratik Shah; Co-Founder, President, and Chairperson; Design Therapeutics, Inc. Operator And welcome to design's conference call at this time. All ...
Q4 2023 Design Therapeutics Inc Earnings Call
Q4 2023 Design Therapeutics Inc Earnings Call Q4 2023 Design Therapeutics Inc Earnings Call HOME MAIL NEWS FINANCE SPORT CELEBRITY STYLE WEATHER MORE... Yahoo Finance Sign in Mail Sign in to view your ...
Loading the latest forecasts...